Losartan in clinical studies
Authors:
prof. MUDr. Jindřich Špinar, CSc.; Fesc 1; Prof. MUDr. Jiří Vítovec, CSc.; Fesc 2
Authors‘ workplace:
Interní kardiologická klinika
FN Brno-Bohunice
1; I. interní kardioangiologická klinika
FN U svaté Anny, Brno
2
Published in:
Kardiol Rev Int Med 2005, 7(4): 195-200
Category:
Editorial
Overview
Losartan is a long-acting angiotensin-II receptor blocker which is widely prescribed in the U.S. and in Europe including Czech Republic. It is produced in doses 50 and 100 mg and in combination with hydrochlorthiazidum. Its efficacy was proved in mortality studies in heart failure (ELITE II), after myocardial infarction (OPTIMAAL) an in hypertension (LIFE). It is verified in diabetic nephropathy (RENAAL). It has provided a greater decrease of strokes and new cases of diabetes than atenolol. We are presenting our experiences with losartan in two studies after myocardial infarction and in one international study in hypertension.
Sources
1. American Diabetes Association: Diabetic Nefropathy. Diabetes Care 2002; 25(Suppl 1): 85–89.
2. Brenner BM, Cooper ME, Zeeuw D for the RENAAL investigators: RENAAL: Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan. Effects of Losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
3. Bultas J. Blokátory receptorů AT1 ve světle medicíny založené na důkazech. JACC-CZ 2003; 4: 247–248.
4. Carson P, Gilda T, Higginbotham M et al. Angiotensin Receptor Blockers: Evidence for Preserving Target Organs. Clin Cardiol 2001; 24: 183–90.
5. Cífková R, Horký K, Widimský J sr et al. Doporučení diagnostických a léčebných postupů u arteriální hypertenze – verze 2004. Doporučení České společnosti pro hypertenzi. Vnitř lék 2004; 50: 709–22.
6. Dahlof B, Devereux RB, Kjeldsen SE for the LIFE investigators: Cardovascular morbidity and mortality in the Losartan Intervention For Endpoints reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003.
7. Dickstein K, Kjekshus J and OPTIMAAL Study Group. Effects od losartan nad captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL ransomised trial. Lancet 2002; 360: 752–760.
8. Jong P, Demers C, McKelvie RS, Liu PP. Angiotensin Receptor Blockers in Heart Failure. Meta-Analysis of Randomized Controlled Trials. J Am Coll Cardiol 2002; 39: 463–470.
9. Pitt B, Poole-Wilson PA, Segal R et al on behalf of the ELITE II Investigators. ELITE II (Effects of Losartan Versus Captopril on Mortality in Patients With Symptomatic Heart Failure). Lancet 2000; 355: 1582–1587.
10. Špinar J, Vítovec J, Špinarová L et al. A comparison of intervention with losartan or captopril in acute myocardial infarction. Eur J Heart Failure 2000; 2: 91–100.
11. Špinar J, Vítovec J, Pluháček L et al. First dose hypotension after angiotenzin converting enzyme inhibitor captopril and angiotensin II blocker losartan in patients with acute myocardial infarction. Int J Cardiol 2000; 75: 197–204.
12. Špinar J, Ludka O, Svoboda J et al. Srovnání léčby hypertenze na interní klinice FN, na interním oddělení malé nemocnice a na specializované kaediologické klinice. Kardiol Rev 2005; 7(2): 83–89.
13. Špinar J. Blokátory receptoru 1 pro angiotenzin II a ledviny. Cor Vasa 2002; 44: 433–436.
14. Špinar J, Souček M, Vítovec J et al. Studie LORISTA: účinnost a snášenlivost losartanu u pacientů s esenciální hypertenzí: multicentrická, dvojitě slepá srovnávací studie losartanu s metoprololem. Kardiol Rev 2002; 4: 225–231.
15. Špinar J, Vítovec J. AII antagonisté vytáhli trumfové eso – studie LIFE a SCOPE. Cor Vasa 2002; 44: 537–540.
16. Šváb P. Kardiovaskulární účinky antagonistů II. Remedia 2003; 13: 142–147.
17. Vítovec J, Špinar J. Blokátory receptoru I pro angiotenzin II (ARB) v léčbě srdečního selhání. Int Med Prax 2003; 5: 386–388.
18. Vítovec J, Špinar J. Antagonisté receptoru AT1 pro angiotenzin II(ARB) v léčbě hypertenze STUDIE LIFE. Klin Farmakol Farm 2003; 17: 43–45.
19. Vítovec J, Špinar J. Mohou blokátory receptorů pro angiotenzin II (AIIA) nahradit v léčbě srdečního selhání inhibitory ACE? Cor Vasa 2003; 45: 169–170.
20. Zanchetti A for the guidelines committee. 2003 European Society of Hypertension – European Society of Cardiology guidelines for the management of arterial hypertension. J Hyperten 2003; 21: 1011–23.
21. Azizi M, Menárd J. Combined Blockade of the Renin-Angiotensin Systém With Angiotensin-Converting Enzyme Inhibititors and Angiotensin II Type 1 Receptor Antagonists. Circulation 2004; 109: 2492–2499.
Labels
Paediatric cardiology Internal medicine Cardiac surgery CardiologyArticle was published in
Cardiology Review
2005 Issue 4
Most read in this issue
- Left Main Coronary Artery Occlusion Induced Acute Myocardial Infarction: Experiences from the Beginning of the Third Millenium
- Losartan in clinical studies
- Rehabilitation after myocardial infarction (III)
- Coronary artery disease and kidney disease